MAPT and Alzheimer disease: Despite the method was not fully validated for the NGF peak, unlike the proNGF one (see validation in Malerba et al., 2021), we compared multivariate models using the set of clinically validated biomarkers (Aβ42, Tau, and pTau) as covariates predicting the disease diagnosis, to the same models with the contribution of NGF or NGF and proNGF as additional covariates, for the comparison between FTD and AD, FTD and SMC_CTR (we again pooled CTR and SMC subjects).